Information Provided By: 
Fly News Breaks for March 22, 2019
ESALY
Mar 22, 2019 | 06:06 EDT
Nomura Instinet analyst Motoya Kohtani double downgraded Eisai to Reduce from Buy and lowered his price target for the shares to 6,000 yen from 17,000 yen following the cancellation of the Phase 3 trial of aducanumab. The analyst said he had high expectations for the drug.
News For ESALY From the Last 2 Days
There are no results for your query ESALY
